340B claims aren’t eligible for manufacturer rebates; but 340B confusion is still costing organizations millions.
In 2025, as more manufacturers enforce strict rebate submission criteria, health systems and payers are finding that poor documentation or unclear drug sourcing can result in denied rebates, even when a claim is commercially eligible.
The New Reality of Rebate Submissions
Here’s what’s creating problems in the field:
- Drug manufacturers are tightening validation requirements.
They want confirmation that the drug was not purchased through a 340B account. - White-bagging, contract pharmacy, and GPO procurement overlap
makes it harder to confidently flag sourcing at the point of submission. - HRSA’s 340B audit pressure is prompting more conservative documentation standards, especially in infusion centers and outpatient care.
If your submission framework can’t prove the claim was sourced appropriately, manufacturers may withhold rebates—even when your team did everything right on the care side.
What This Means for Rebate Strategy
Too often, we see:
- Claims submitted without sourcing clarity
- 340B-flagged encounters accidentally included in rebate cycles
- Missing documentation that makes defensibility impossible during audit
The result? Rebates lost—not because of ineligibility, but because of gaps in data integrity.
How VativoRx Helps
At VativoRx, we work with clients to minimize this risk by:
- Auditing and mapping sourcing paths across service sites
- Structuring rebate submissions to align with each manufacturer’s compliance rules
- Ensuring 340B and GPO exclusions are correctly applied at the claim level
We also help teams implement frameworks that support auditability—so future disputes don’t become future disqualifications.
You Can’t Afford Rebate Rejections Due to Documentation Gaps
As rebate programs evolve, so must the way organizations manage sourcing data and submission protocols.
If your team is feeling the complexity of balancing 340B programs and rebate recovery, we can help.
Contact us to schedule a risk-free rebate opportunity review.
